Pharmacological Treatment of Obesity: A Review of Current and Future Methods
DOI:
https://doi.org/10.12775/QS.2024.22.54691Keywords
obesity, overweight, GLP-1 receptor agonist, SGLT2-inhibitors, obesity treatment, anti-obesity agentsAbstract
Introduction and objective Obesity poses a significant public health challenge due to its association with an elevated risk of various chronic diseases, including cardiovascular conditions, type 2 diabetes, and overall mortality. While lifestyle modifications such as dietary changes and increased physical activity remain cornerstone interventions in obesity management, pharmacological treatments have emerged as an adjunctive approach to address this complex condition. The review aims to compare the effectiveness of current pharmacotherapy and show upcoming methods of treatment of obesity. Review methods The review was conducted by searching scientific publications in PubMed, Google Scholar, Clinicaltrials.gov, Summaries of Product Characteristics, URPL, FDA, and EMA databases. The articles on medications available in Poland for treating obesity and the latest clinical trials of upcoming drugs were analyzed, followed by a concise review of the collected data. Abbreviated description of the state of knowledge Currently, in the Polish market, medications available for obesity treatment include orlistat, the combination of naltrexone and bupropion, liraglutide, tirzepatide, and available as part of the target import - semaglutide. Promising clinical trials are being conducted on further medications for weight reduction, including retatrutide, orforglipron, cagrilintide, and amycretin. Regrettably, new and effective medications due to their high cost and insufficient funding. Summary New pharmacotherapy options for obesity, particularly anti-diabetic medications, are rapidly advancing. Glucagon-like peptide-1 (GLP-1) analogs have shown promising results in weight reduction, surpassing previous medications such as orlistat or naltrexone. Recent drugs offer weight loss ranging up to 25%. More studies are underway on novel and increasingly effective medications.References
WHO. Obesity and overweight. March,2024 https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight(access: 2024.08.04).
WHO. A healthy lifestyle - WHO recommendations. https://www.who.int/europe/news-room/fact-sheets/item/a-healthy-lifestyle---who-recommendations (access: 2024.08.04).
Szczeklik A. Interna Szczeklika 2022. In: Piotr Gajewski [et al.] (eds.), 13th ed. Kraków, 2022, Medycyna Praktyczna, p. 2741-2743.
Engin AB. What Is Lipotoxicity? Adv Exp Med Biol. 2017; 960: 197-220. doi: 10.1007/978-3-319-48382-5_8. PMID: 28585200.
GUS. Odsetek osób w wieku powyżej 15 lat według indeksu masy ciała (BMI) https://stat.gov.pl/obszary-tematyczne/zdrowie/zdrowie/odsetek-osob-w-wieku-powyzej-15-lat-wedlug-indeksu-masy-ciala-bmi,23,1.html (access: 2024.08.04).
Ministerstwo Zdrowia. Narodowy Program Zdrowia na lata 2021-2025 https://www.gov.pl/web/zdrowie/npz-2021-2025(access: 2024.08.04).
Rejestr produktów leczniczych. https://rejestry.ezdrowie.gov.pl/rpl/search/public (access: 2024.08.05).
Fisher R. American Diabetes Association Highlights Novel Agent Retatrutide which Results in Substantial Weight Reduction in People with Obesity or Type 2 Diabetes During Late Breaking Symposium. https://diabetes.org/sites/default/files/2023-10/ada_sci_sessions_2023_news_release_retatrutide_0.pdf (access: 2024.08.05).
Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight https://investor.lilly.com/node/49091/pdf (access: 2024.08.05).
Bansal AB, Al Khalili Y. Orlistat. https://www.ncbi.nlm.nih.gov/books/NBK542202/ (access: 2024.08.05).
Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004 Jan;27(1):155-61. doi: 10.2337/diacare.27.1.155. Erratum in: Diabetes Care. 2004 Mar;27(3):856. PMID: 14693982.
Plodkowski RA, Nguyen Q, Sundaram U, et al. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin Pharmacother. 2009 Apr;10(6):1069-81. doi: 10.1517/14656560902775750. PMID: 19364254.
Summary of product characteristics Mysimba https://www.ema.europa.eu/en/documents/product-information/mysimba-epar-product-information_en.pdf (access: 2024.08.06).
Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29. Erratum in: Lancet. 2010 Aug 21;376(9741):594. Erratum in: Lancet. 2010 Oct 23;376(9750):1392. PMID: 20673995.
Summary of product characteristics Saxenda https://www.ema.europa.eu/en/documents/product-information/saxenda-epar-product-information_en.pdf (access: 2024.08.07).
Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892. PMID: 26132939.
Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015 Aug 18;314(7):687-99. doi: 10.1001/jama.2015.9676. Erratum in: JAMA. 2016 Jan 5;315(1):90. PMID: 26284720.
Summary of product characteristics Wegovy https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf (access: 2024.08.08).
Wilding JPH, Batterham RL, Calanna S et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.
Davies M, Færch L, Jeppesen OK et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0. Epub 2021 Mar 2. PMID: 33667417.
Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001/jama.2021.1831. PMID: 33625476; PMCID: PMC7905697.
Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224. PMID: 33755728; PMCID: PMC7988425.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Sep 21;389(12):1069-1084. doi: 10.1056/NEJMoa2306963. Epub 2023 Aug 25. PMID: 37622681.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. PMID: 37952131.
Summary of product characteristics Mounjaro https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf (access: 2024.08.19)
EMA. Mounjaro - opinion on variationto marketing authorization https://www.ema.europa.eu/en/medicines/human/variation/mounjaro (access: 2024.08.19).
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.
Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. PMID: 37385275.
Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023 Nov;29(11):2909-2918. https://doi.org/10.1038/s41591-023-02597-w
Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024 Jan 2;331(1):38-48. doi: 10.1001/jama.2023.24945. PMID: 38078870; PMCID: PMC10714284.
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5) https://clinicaltrials.gov/study/NCT05822830#publications (access: 2024.08.20).
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26. PMID: 37366315.
Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26. PMID: 37385280.
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1) https://clinicaltrials.gov/study/NCT05929066?term=retatrutide&aggFilters=phase:3&rank=4 (access: 2024.08.20).
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2) https://clinicaltrials.gov/study/NCT05929079?term=retatrutide&aggFilters=phase:3&rank=5 (ss: 2024.08.20).
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) https://clinicaltrials.gov/study/NCT05882045?term=retatrutide&aggFilters=phase:3&rank=3 (access: 2024.08.20).
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4) https://clinicaltrials.gov/study/NCT05931367?term=retatrutide&aggFilters=phase:3&rank=6 (access: 2024.08.20).
Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023 Sep 7;389(10):877-888. doi: 10.1056/NEJMoa2302392. Epub 2023 Jun 23. PMID: 37351564.
Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023 Aug 5;402(10400):472-483. doi: 10.1016/S0140-6736(23)01302-8. Epub 2023 Jun 24. Erratum in: Lancet. 2023 Sep 2;402(10404):774. PMID: 37369232.
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) https://clinicaltrials.gov/study/NCT05869903?intr=Orforglipron&rank=6 (access: 2024.08.20).
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2) https://clinicaltrials.gov/study/NCT05872620?intr=Orforglipron&rank=5 (access: 2024.08.20).
Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023 Aug 26;402(10403):720-730. doi: 10.1016/S0140-6736(23)01163-7. Epub 2023 Jun 23. PMID: 37364590.
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight (REDEFINE 1) https://clinicaltrials.gov/study/NCT05567796?intr=CagriSema&term=REDEFINE&rank=4 (access: 2024.08.21).
Novo Nordisk. Research and early development. https://cdn.evenzu.io/event/hxr1zomb2k05vitfdy6lsua3j7c8pe9n/file/evev269_d1709793399.pdf (access: 2024.08.21).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Angelina Lęgas, Joanna Smalira, Bartosz Przybysz, Jakub Kawalec, Julia Zawistowska, Karolina Rogowska, Katarzyna Pochodowicz, Weronika Rogala, Weronika Rutkowska-Kawalec, Karolina Urbańska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 31
Number of citations: 0